AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $249,000 | -5.0% | 5,750 | -23.3% | 0.10% | -21.0% |
| Q3 2020 | $262,000 | -34.7% | 7,500 | 0.0% | 0.12% | -37.4% |
| Q2 2020 | $401,000 | +24.1% | 7,500 | -17.6% | 0.20% | -3.9% |
| Q1 2020 | $323,000 | -25.7% | 9,100 | 0.0% | 0.21% | -1.0% |
| Q4 2019 | $435,000 | -6.9% | 9,100 | -36.8% | 0.21% | -10.0% |
| Q3 2019 | $467,000 | -33.1% | 14,400 | +2.9% | 0.23% | -39.5% |
| Q2 2019 | $698,000 | -33.2% | 14,000 | -9.7% | 0.38% | -31.5% |
| Q1 2019 | $1,045,000 | +40.8% | 15,500 | -3.7% | 0.56% | +16.7% |
| Q4 2018 | $742,000 | -61.8% | 16,100 | -36.0% | 0.48% | -53.4% |
| Q3 2018 | $1,940,000 | -8.4% | 25,150 | 0.0% | 1.02% | -10.3% |
| Q2 2018 | $2,118,000 | +3.0% | 25,150 | 0.0% | 1.14% | -0.4% |
| Q1 2018 | $2,057,000 | +30.6% | 25,150 | -8.7% | 1.15% | +36.3% |
| Q4 2017 | $1,575,000 | -15.3% | 27,550 | -1.1% | 0.84% | -27.7% |
| Q3 2017 | $1,859,000 | – | 27,850 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |